Southwest Oncology Group researchers have found that starting Keytruda (pembrolizumab) before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
